PluroGen Therapeutics, Inc.
2495 General Armistead Avenue
Norristwon, Pennsylvania 19403
Tel: +1 (434) 563-4321
Fax: +1 (434) 563-4322
(Norristown, PA, 20 January 2011) – PluroGen Therapeutics, Inc. today announced that it has expanded its
operations moving into its own 21,000 sq. ft. facility in Norristown, PA. PluroGen’s new facility houses a
multiple-room ISO 6 clean-room for product manufactuing, laboratory space, climate-controlled warehousing
Neal G. Koller, President & CEO of PluroGen, remarks, “Our new facility provides PluroGen the ability to
make and deliver our ground-breaking products:
• Single-Antibiotic PluroGel® SSD just launched for our European customers and their patients
• Triple-Antibiotic PluroGel® PNN for our $8.6M contract with US DoD to obtain FDA approval)
• And PluroGel® only concentrate for our skin & wound cleansing wet wipes partner in Europe”
“The new facility provides us with the space and capacity to hire the addtional personnel and place the
needed production equipment to support our US Depatment of Defense award and our worldwide demand for
PluroGel® products. PluroGen now has the manufacturing and operations platform needed to support our
sales growth for a number years into the future. This is a very important and milestone step forward for the
About PluroGen Therapeutics, Inc.
PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology
platforms. The Company’s primary platform is its core PluroGel® technology which provides paradigm-
shifting, superior and differentiated physical, bio-impact, and multi-function products. PluroGel® is University
developed and is in routine use at the University, having shown superior results on more than 10,000
patients in two different patient populations - severe burns and wounds. PluroGen’s three technology
platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key
areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4.
Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration.
PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel®
branded topical antimicrobial prescription products and PluroGel® co-branded products with select
PluroGen’s senior management, operations team, boards and principal investigators are all recognized
global commercial and clinical leaders in PluroGen’s target markets of burn and wound care.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. PluroGen cautions readers that forward-looking statements are subject
to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time
in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the
protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.
Contact: Neal G. Koller
President & CEO
Board of Directors
+1 (434) 563-4321
|PluroGen Expands into its Own 21,000 sq. ft. Multi-Purpose Facility